Drugs / US-DARZALEX FASPRO®
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07477587 Comparator | May 2026 → May 2027 expected | plasma cell myeloma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | US-DARZALEX FASPRO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07477587 ↗ |
| Route | Subcutaneous | “via SC administration” NCT07477587 ↗ |